FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1176-1180 April 17, 1997 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Attacks on health researchers are not new. Pierre Louis, for example, was vilified nearly two centuries ago for suggesting that bloodletting was an ineffectual therapy.¹ In an open society such as ours, controversy is common and often socially useful. The fact that scientists are sometimes challenged by special-interest groups should be no surprise. However, with widening media coverage of health research, growing public interest in health hazards, and expanding research on the outcomes of clinical care, such attacks may become more frequent and acrimonious. The huge financial implications of many research studies invite vigorous attack.

In Marcia Angell's recent Shattuck . . . [Full Text of this Article]

Case Reports

Case 1: Spinal-Fusion Surgery

Case 2: Multiple Chemical Sensitivity

Case 3: Pharmaceuticals

Terms of Discourse

Costs to Society and Possible Remedies

Protection of Findings

Protection of Investigators

Protection of Funding Agencies

The Need to Support Disinterested Research

Address reprint requests to Dr. Deyo at the Center for Cost and Outcomes Research, 146 N. Canal St., Suite 300, Seattle, WA 98103-8652.

References

Related Letters:

Intimidation of Researchers by Special-Interest Groups
Donnay A., Baker G. P., Fardon D. F., Garfin S. R., Saal J. A., Simon G., Deyo R. A., Sternberg E. M., Gordon D. A., Brodkin C. A., Mohr S., Frumkin H., Marsh D. J., Scott H. D., Fulks J. R., Kern D. G., Durand K. T.H.
Extract | Full Text  
N Engl J Med 1997; 337:1314-1319, Oct 30, 1997. Correspondence

This article has been cited by other articles:

• Lenzer, J. (2009). Watching over the medical device industry. BMJ 338: b2321-b2321 [Full Text]  
• Benos, D. J., Bashari, E., Chaves, J. M., Gaggar, A., Kapoor, N., LaFrance, M., Mans, R., Mayhew, D., McGowan, S., Polter, A., Qadri, Y., Sarfare, S., Schultz, K., Splittgerber, R., Stephenson, J., Tower, C., Walton, R. G., Zotov, A. (2007). The ups and downs of peer review. Adv. Physiol. Educ. 31: 145-152 [Abstract] [Full Text]  
• Steinbrook, R. (2007). Guidance for Guidelines. NEJM 356: 331-333 [Full Text]  
• Jacobs, J. J., Galante, J. O., Mirza, S. K., Zdeblick, T. (2006). Symposium. Relationships with Industry: Critical for New Technology or an Unnecessary Evil?. JBJS 88: 1650-1663 [Full Text]  
• Schachman, H. K. (2006). From "publish or perish" to "patent and prosper".. J. Biol. Chem. 281: 6889-6903 [Full Text]  
• Ungar, S., Bray, D. (2005). Silencing science: partisanship and the career of a publication disputing the dangers of secondhand smoke. Public Understanding of Science 14: 5-23 [Abstract]  
• Geyman, J. P. (2003). The Corporate Transformation of Medicine and Its Impact on Costs and Access to Care. J Am Board Fam Med 16: 443-454 [Full Text]  
• Rossignol, M (2003). The management of low back pain. Occup. Environ. Med. 60: 617-617 [Full Text]  
• Butterworth, J., Furberg, C. D. (2003). Improving Cardiac Outcomes After Noncardiac Surgery. Anesth. Analg. 97: 613-615 [Full Text]  
• Baird, P. (2003). Getting it right: industry sponsorship and medical research. CMAJ 168: 1267-1269 [Full Text]  
• Page, L A, Wessely, S (2003). Medically unexplained symptoms: exacerbating factors in the doctor-patient encounter. JRSM 96: 223-227 [Full Text]  
• Fischhoff, B., Wessely, S. (2003). Managing patients with inexplicable health problems. BMJ 326: 595-597 [Full Text]  
• Deyo, R A (2002). Bruce Psaty and the risks of calcium channel blockers. Qual Saf Health Care 11: 294-296 [Full Text]  
• Rosenstock, L., Lee, L. J. (2002). Attacks on Science: The Risks to Evidence-Based Policy. AJPH 92: 14-18 [Abstract] [Full Text]  
• Wessely, S. (2001). Chronic Fatigue Syndrome--Trials and Tribulations. JAMA 286: 1378-1379 [Full Text]  
• Becher, E. C., Chassin, M. R. (2001). Improving The Quality Of Health Care: Who Will Lead?. Health Aff (Millwood) 20: 164-179 [Abstract] [Full Text]  
• Satya-Murti, S. (2000). Evidence-Based Clinical Practice: Concepts and Approaches. JAMA 283: 2306-2307 [Full Text]  
• Andrews, G. (1999). Randomised controlled trials in psychiatry: important but poorly accepted. BMJ 319: 562-564 [Full Text]  
• Fisher, E. S., Welch, H. G. (1999). Avoiding the Unintended Consequences of Growth in Medical Care: How Might More Be Worse?. JAMA 281: 446-453 [Abstract] [Full Text]  
• Richardson, D., Tarnow-Mordi, W. O., Pollack, M. M. (1998). Proprietary Products and Research: The Proponents' View. Pediatrics 102: 401-403 [Full Text]  
• Donnay, A., Baker, G. P., Fardon, D. F., Garfin, S. R., Saal, J. A., Simon, G., Deyo, R. A., Sternberg, E. M., Gordon, D. A., Brodkin, C. A., Mohr, S., Frumkin, H., Marsh, D. J., Scott, H. D., Fulks, J. R., Kern, D. G., Durand, K. T.H. (1997). Intimidation of Researchers by Special-Interest Groups. NEJM 337: 1314-1319 [Full Text]